SYNERGY™

Monorail

Everolimus-Eluting Platinum Chromium Coronary Stent System

Early Healing

Abluminal bioabsorbable polymer (BP) application

Emphasizes suppression of neointimal growth at the arterial wall while promoting healing inside the vessel.



Thin, rounded struts

Stents with thinner strut designs have been shown to heal faster than thicker strut stents.1

SYNERGY™ XD

Fast-absorbing bioabsorbable polymer

Polymer is gone when it is no longer needed, shortly after the drug is completely eluted.2



Optimal drug release

Market-leading Everolimusdrug is completely eluted with optimal kinetics at 3 months.

Lower Inflammation Rates3

In a preclinical model, SYNERGY™ BP Stent demonstrated:

  • Significantly reduced Early Inflammation versus Bare Metal Stents (BMS)
  • Significantly reduced Late Inflammation versus Permanent Polymer (PP) Stents
Lower Inflammation Rates

Not All Bioabsorbable Polymer Stents are Created Equal

BP Stents differ in terms of polymer application, polymer type, polymer absorption time, drug type, drug elution times and stent design.
Not All Bioabsorbable Polymer Stents are Created Equal

Optimal Healing Shown Through Strut Coverage and Angioscopy

SYNERGY™ BP Stent has shown full stent strut coverage as early as 30-days in humans and showed 0% stent thrombosis in all of these OCT analyses.6
Optimal Healing Shown Through Strut Coverage and Angioscopy

 

Angioscopy demonstrates differentiated and improved healing with SYNERGY™ BP Stent.9

Angioscopy is also able to detect the quality of neointimal coverage that we are not able to see with OCT.

Angioscopy demonstrates differentiated and improved healing with SYNERGY BP Stent.
* Boston Scientific data on file.
† Images courtesy of Takafumi Ueno, MD; Division of Cardiovascular Medicine, Kurume University School of Medicine, Kureme, Japan.
‡ Image captured at 13-month follow-up
. § Image captured at 12-month follow-up

Syntax II Trial

The SYNTAX II Trial utilizing SYNERGYTM BP Stent, physiological assessment, IVUS guidance, and contemporary state-of-the-art PCI techniques, demonstrated equivalent outcomes to CABG in patients with three-vessel disease at 2-years.*13
Syntax II Trail

Consistent CTO Study

The SYNERGY™ BP Stent combined with up-to-date techniques demonstrated low event rates in complex lesions (mean stent length 85.6 mm, JCTO Score 2.4) and very symptomatic patients at 12-months.*14
CONSISTENT CTO Study
*angiographically detected
SYNERGY™ Clinical Overview

SYNERGY™ Clinical Overview

Discover the clinical evidence on the SYNERGY™ BP Stent, including multiple short DAPT studies.

Button
Exceptional Deliverability

Exceptional Deliverability

Learn about the continued advancement in deliverability that SYNERGY™ offers.

Button
SYNERGY™ 48 mm

SYNERGY™ 48 mm

Discover the FIRST and ONLY 48 mm DES.

Button
 
Top